Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
FDA-labeled warnings include: Risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Pancreatitis (report severe abdominal pain, with or without vomiting) Gallbladder disease (including gallstones and cholecystitis) Acute kidney injury secondary to dehydration from gastrointestinal symptoms Hypoglycemia when used with insulin or insulin secretagogues (dose adjustments may be needed) Diabetic retinopathy complications in patients with type 2 diabetes and pre-existing retinopathy Suicidal behavior and ideation (monitor for depression or suicidal thoughts) Intestinal obstruction/ileus (particularly with severe constipation) These medications are contraindicated during pregnancy and should be discontinued at least two months before a planned pregnancy
Administration: Subcutaneous (SubQ) injection, typically once per week
Over time, this immune-mediated injury can progress to fibrosis, cirrhosis, and HCC
Who Benefits Most Men most likely to see testosterone improvements from tirzepatide include those with: BMI above 30, especially with visceral obesity Documented obesity-related hypogonadism (low T with elevated BMI) Insulin resistance or type 2 diabetes Total testosterone in the borderline-low range (250-400 ng/dL) Symptoms of low T that emerged alongside weight gain Men with primary hypogonadism (testicular failure) or pituitary disorders are unlikely to see testosterone restoration from weight loss alone and will still require direct hormone replacement
13 : 909916 Aureli T, Miccheli A, Ricciolini R, Di Cocco ME, Ramacci MT, Angelucci L et al
US$ 29.19
US$ 22.32
US$ 29.21
US$ 28.74
US$ 29.02
